A phase I dose-escalating study of induction gemcitabine/pemetrexed followed by pemetrexed and concurrent upper abdominal radiation therapy in patients with locally advanced pancreatic cancer.

Trial Profile

A phase I dose-escalating study of induction gemcitabine/pemetrexed followed by pemetrexed and concurrent upper abdominal radiation therapy in patients with locally advanced pancreatic cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Pemetrexed (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jun 2008 The expected planned completion date changed from 1 Oct 2009 to actual completion date 1 May 2008.
    • 17 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2008 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top